ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Biological multi-omics approaches to next-generation biomarkers in immune-related disorders and malignancies: An overview.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cell-based therapies of autoimmune diseases in the context of artificial intelligence development.Clinical and experimental medicine · 2026Review
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Review
- Metabolic reprogramming in diabetes and cancer: the role of PI3K/AKT/mTOR and beyond.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer and autoimmune diseases are major global health challenges characterized by molecular and clinical heterogeneity. Traditional single-analyte biomarkers often lack the sensitivity and specificity required for early detection and personalized therapy, highlighting the need for robust next-generation biomarkers (NGBs). This review provides a concise overview of NGBs in cancer and autoimmune diseases, emphasizing multi-omics integration and artificial intelligence (AI)-driven approaches shaping precision diagnostics and therapeutics. A literature search of PubMed, Scopus, and Web of Science over the last 15 years focused on genomics, transcriptomics, spatial transcriptomics, proteomics, metabolomics, and Microbiomics, particularly studies combining multi-omics datasets with AI/machine learning. Multi-omics and AI reveal dynamic molecular signatures-circulating tumor DNA, microRNAs, long non-coding RNAs, proteins, metabolites, and immune profiles. Single-cell and spatial analyses uncover cellular heterogeneity and tissue context, while proteomics, metabolomics, and microbiomics provide functional insights, enhancing disease detection, patient stratification, and therapy monitoring. Challenges include assay standardization, inter-patient variability, and regulatory hurdles. Multi-omics and AI-powered NGBs promise to transform precision diagnostics and personalized therapy, requiring continued research, standardization, and global collaboration.
Indexed as
Identifiers
41324821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.